ESMO 2023: Expert Perspectives & Insights into the Testing and Treatment of Melanoma - Episode 10

Efficacy and Safety of Rechallenge With BRAF/MEK Inhibitors in Patients With BRAF-Mutated Metastatic Melanoma

December 14, 2023

Michael Postow, MD, John M. Kirkwood, MD, Meredith McKean, MD, MPH, Helen Moon, MD, Sapna Patel, BA, MD

Panelists discuss the potential benefits of rechallenging patients with BRAF-mutated metastatic melanoma with BRAF/MEK inhibitors after a break from treatment, especially for those who initially responded well, and emphasizing the success of this approach in some cases, while highlighting the importance of monitoring and utilizing ctDNA tracking for more informed decision-making.

EP. 1: The Role of Biomarker Testing in the Management of Metastatic Melanoma

EP. 2: Best Practices for Biomarker Testing in Metastatic Melanoma

EP. 3: Differences Between Community and Academic Settings Regarding Biomarker Testing Practices in Metastatic Melanoma

EP. 4: Treatment Options for Patients With Metastatic Melanoma With a BRAF Mutation

EP. 5: Factors Influencing Treatment Decision-Making In Patients With BRAF-Mutated Metastatic Melanoma

EP. 6: Frontline Treatment Options for Patients With BRAF-Mutated Metastatic Melanoma

EP. 7: Common Adverse Effects Seen With BRAF/MEK Inhibitor Therapy in Patients With BRAF-Mutated Metastatic Melanoma

EP. 8: Choosing Between Available Combination BRAF/MEK Inhibitor Options for Patients With BRAF-Mutated Metastatic Melanoma

EP. 9: Encorafenib Plus Binimetinib for BRAF-Mutated Metastatic Melanoma: 7-Year Follow-Up Data From the COLUMBUS Trial

Now Viewing

EP. 10: Efficacy and Safety of Rechallenge With BRAF/MEK Inhibitors in Patients With BRAF-Mutated Metastatic Melanoma

EP. 11: Treatment Approaches For Patients With BRAF-Mutated Melanoma and Asymptomatic Brain Metastases